Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782470 · ClinicalTrials.gov registry record
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 38
- Enrollment target
NCT00782470 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 38 participants.
The verdict
NCT00782470 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
Understanding how often the bleeding events occur in the subjects who voluntarily decide to switch from prophylaxis to on-demand and in those subjects who remain on prophylaxis. Also look into the consequences of switching treatment in QoL (quality of life), development of target joints, activity level and reasons that might influence the desire to switch.
Interventions
- BEHAVIORAL Recombinant Factor VIII (Kogenate, BAY 14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782470
The ClinicalTrials.gov registry entry for NCT00782470 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Factor VIII (Kogenate, BAY 14-2222) is the first listed.
NCT00782470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782470 about?
NCT00782470 is a clinical study titled "Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A". Understanding how often the bleeding events occur in the subjects who voluntarily decide to switch from prophylaxis to on-demand and in those subjects who remain on prophylaxis. Also look into the consequences of switching treatment in QoL (quality of life), development of target joints, activity le...
What is the current status of trial NCT00782470?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2007-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00782470?
The interventions under investigation include: Recombinant Factor VIII (Kogenate, BAY 14-2222) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00782470?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.